Comparing results from multiple imputation and dynamic marginal structural models for estimating when to start antiretroviral therapy
暂无分享,去创建一个
Bryan E Shepherd | Qi Liu | Nathaniel Mercaldo | Cathy A Jenkins | Bryan Lau | Stephen R Cole | Michael S Saag | Timothy R Sterling | S. Cole | B. Lau | T. Sterling | M. Saag | C. Jenkins | B. Shepherd | N. Mercaldo | Qi Liu
[1] Michael J Silverberg,et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.
[2] J. Robins,et al. Estimation and extrapolation of optimal treatment and testing strategies , 2008, Statistics in medicine.
[3] R B D'Agostino,et al. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. , 1990, Statistics in medicine.
[4] Richard D Moore,et al. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. , 2008, International journal of epidemiology.
[5] S. Cole,et al. Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies , 2004, Statistics in medicine.
[6] R. Pomerantz. Initiating antiretroviral therapy during HIV infection: confusion and clarity. , 2001, JAMA.
[7] Sally S Bebawy,et al. Estimating the Optimal CD4 Count for HIV-infected Persons to Start Antiretroviral Therapy , 2010, Epidemiology.
[8] Roger A. Sugden,et al. Multiple Imputation for Nonresponse in Surveys , 1988 .
[9] S. Vermund,et al. Impact of definitions of loss to follow-up on estimates of retention, disease progression, and mortality: application to an HIV program in Mozambique. , 2013, American journal of epidemiology.
[10] J. Robins,et al. G-Estimation of the Effect of Prophylaxis Therapy for Pneumocystis carinii Pneumonia on the Survival of AIDS Patients , 1992, Epidemiology.
[11] S. Buchbinder,et al. Early versus deferred antiretroviral therapy for HIV. , 2009, The New England journal of medicine.
[12] J. Robins,et al. Comparison of dynamic treatment regimes via inverse probability weighting. , 2006, Basic & clinical pharmacology & toxicology.
[13] James M. Robins,et al. The International Journal of Biostatistics CAUSAL INFERENCE When to Start Treatment ? A Systematic Approach to the Comparison of Dynamic Regimes Using Observational Data , 2011 .
[14] J. Lundgren,et al. When to start antiretroviral therapy: the need for an evidence base during early HIV infection , 2013, BMC Medicine.
[15] S. Murphy,et al. Optimal dynamic treatment regimes , 2003 .
[16] J. Robins,et al. Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. , 2009, International journal of epidemiology.
[17] J. Carpenter,et al. Optimal CD4 Count for Initiating HIV Treatment , 2014, Epidemiology.
[18] F. Dominici,et al. Reproducible epidemiologic research. , 2006, American journal of epidemiology.
[19] N P Jewell,et al. Statistical models for prevalent cohort data. , 1993, Biometrics.
[20] Marie Davidian,et al. Robust estimation of optimal dynamic treatment regimes for sequential treatment decisions. , 2013, Biometrika.
[21] H. Bang,et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. , 2010, The New England journal of medicine.
[22] M. Saag,et al. When to start antiretroviral therapy: as soon as possible , 2013, BMC Medicine.
[23] Michael Rayment,et al. Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.
[24] Haitao Chu,et al. Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution , 2007, Statistics in medicine.
[25] Stephen R Cole,et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies , 2009, The Lancet.
[26] James M Robins,et al. When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries , 2011, Annals of Internal Medicine.
[27] Stephen R Cole,et al. The consistency statement in causal inference: a definition or an assumption? , 2009, Epidemiology.
[28] M. J. van der Laan,et al. Causal Effect Models for Realistic Individualized Treatment and Intention to Treat Rules , 2007, The international journal of biostatistics.
[29] R. Salamon,et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.
[30] M. J. van der Laan. Targeted Maximum Likelihood Based Causal Inference: Part I , 2010, The international journal of biostatistics.
[31] James M. Robins,et al. Comparative Effectiveness of Dynamic Treatment Regimes: An Application of the Parametric G-Formula , 2011, Statistics in biosciences.
[32] Anastasios A. Tsiatis,et al. Q- and A-learning Methods for Estimating Optimal Dynamic Treatment Regimes , 2012, Statistical science : a review journal of the Institute of Mathematical Statistics.
[33] S. Cole,et al. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. , 2011, Archives of internal medicine.
[34] Sally S Bebawy,et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. , 2009, The Journal of infectious diseases.
[35] H. Lane,et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.
[36] Stephen R Cole,et al. Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.
[37] Mark J van der Laan,et al. Targeted Maximum Likelihood Based Causal Inference: Part II , 2010, The international journal of biostatistics.
[38] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[39] A. Phillips,et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study , 2013, Clinical trials.